Eurofins Scientific SE

Stocks

ERF

FR0014000MR3

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-07-10 am EDT			5-day change	1st Jan Change
68.96 ^EUR	+0.23%		-0.58%	+10.51%

Jun. 30	NFL Biosciences validates industrial-scale production of NFL-102 for smoking cessation
Jun. 04	Eurofins Scientific SE acquired High North Laboratories.	CI

Eurofins Scientific SE: Weekly Report on Share Repurchases From 25th May to 29th May 2026

Published on 06/01/2026 at 11:46 am EDT

Business Wire

Add MarketScreener to your sources

EUROFINS SCIENTIFIC SE

+0.23%

Regulatory News:

Eurofins Scientific SE (Paris:ERF):

Name of the Issuer	Identify code of the Issuer	Transaction day	Identify code of the financial instrument	Total daily volume (in number of shares)	Daily weighted average purchase price of the shares	Market (MIC Code)
EUROFINS SCIENTIFIC	529900JEHFM47DYY3S57	25/05/2026	FR0014000MR3	25 000	62.9108	XPAR
EUROFINS SCIENTIFIC	529900JEHFM47DYY3S57	25/05/2026	FR0014000MR3	5 000	63.1452	CEUX
EUROFINS SCIENTIFIC	529900JEHFM47DYY3S57	26/05/2026	FR0014000MR3	25 000	62.6524	XPAR
EUROFINS SCIENTIFIC	529900JEHFM47DYY3S57	26/05/2026	FR0014000MR3	5 000	62.6112	CEUX
EUROFINS SCIENTIFIC	529900JEHFM47DYY3S57	27/05/2026	FR0014000MR3	30 000	62.5550	XPAR
EUROFINS SCIENTIFIC	529900JEHFM47DYY3S57	27/05/2026	FR0014000MR3	10 000	62.5456	CEUX
EUROFINS SCIENTIFIC	529900JEHFM47DYY3S57	28/05/2026	FR0014000MR3	30 000	61.4394	XPAR
EUROFINS SCIENTIFIC	529900JEHFM47DYY3S57	28/05/2026	FR0014000MR3	10 000	61.4617	CEUX
EUROFINS SCIENTIFIC	529900JEHFM47DYY3S57	29/05/2026	FR0014000MR3	30 000	62.3213	XPAR
EUROFINS SCIENTIFIC	529900JEHFM47DYY3S57	29/05/2026	FR0014000MR3	10 000	62.3032	CEUX
			TOTAL	180 000	62.3358

Transaction details

In accordance with Article 5(1)(b) of Regulation (EU) N° 596/2014 (the Market Abuse Regulation) a full breakdown of the individual trades are disclosed on Eurofins Scientific SE website: https://www.eurofins.com/investors/share-buy-back-programmes

View source version on businesswire.com: https://www.businesswire.com/news/home/20260601304294/en/

Add MarketScreener to your sources

Latest news about Eurofins Scientific SE

Jun. 30	NFL Biosciences validates industrial-scale production of NFL-102 for smoking cessation
Jun. 04	Eurofins Scientific SE acquired High North Laboratories.	CI
May. 14	Eurofins Scientific SE Develops And Offers New Solutions For Hantavirus Detection	CI
May. 11	CAC 40: Luxury and Geopolitics Weigh on Sentiment
May. 11	Eurofins among top CAC 40 decliners as BofA downgrades
Apr. 27	Emeis, Exosens, Thales... stocks to watch today in Paris
Apr. 27	French and Benelux stocks-Factors to watch Monday April 27	RE
Apr. 27	Eurofins Scientific to Launch Share Buyback Program	MT
Apr. 27	Eurofins Scientific to Launch Share Buyback Program	MT
Apr. 24	Casino, Eurofins Scientific, DLSI Group, Verallia... stocks to watch Monday in Paris
Apr. 24	Eurofins launches 7th share buyback program
Apr. 24	Eurofins Scientific launches seventh buy-back programme of its own shares	RE
Apr. 23	Eurofins Scientific: 2026 targets confirmed despite a soft start; reasonable valuation outweighed by uncertainty
Apr. 22	European markets end in the red despite extended ceasefire
Apr. 22	Eurofins Scientific SE, Q1 2026 Sales/ Trading Statement Call, Apr 22, 2026

Chart Eurofins Scientific SE

Duration

Period

ERF: Dynamic Chart

Company Profile

Eurofins Scientific SE is one of the world's leading providers of bio-analytical services. The group's services are intended to validate the safety, authenticity, origin, identity, and purity of biological substances contained in the environment (water, air, soil, etc.) and in food, pharmaceutical, cosmetic, and hygiene products. At the end of 2025, Eurofins Scientific SE owned a portfolio of over 200,000 analytical methods and had 950 laboratories located throughout the world. Net sales are distributed geographically as follows: Europe (52,5%), North America (36.8%) and other (10.7%).

Employees

65,694

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company